I don’t understand your thought process here. If anyone were interested in becoming a share holder of AHZ now it would have to be for the Adapt 3D and TAVR products, which is quite obviously the future direction of this business.
It is the current management team that positioned us in this space so why would a change is management be advised, it makes zero sense to me as they are quite clearly the key to the relationships with our two cornerstone investors. Any agitated change at the top of the tree would be fatal imo.
So if shareholders wish to minimise their losses, get their money back or even make a profit at some stage in the future they should stick the course with current management imo. For any of those 3 options to transpire we will need infusion gone and a TAVR partner at a minimum.
Ann: Promising Interim Results from TAVR Animal Study, page-60
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.75 |
Change
-0.160(0.89%) |
Mkt cap ! $341.1M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.65 | $53.47K | 2.992K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 285 | $17.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.75 | 2141 | 1 |
View Market Depth
| Last trade - 15.58pm 16/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |